New Delhi, May 22 -- Sun Pharmaceutical Industries Ltd will continue to focus on its specialty products in FY26, which contributed to India's largest drugmaker's growth last fiscal.

The company plans to invest an additional $100 million on the commercialization of its new specialty product pipeline in the US, chairman and managing director Dilip Shanghvi said in an earnings call on Thursday.

Also Read | Sun Pharma can launch alopecia drug Leqselvi in US as court removes injunction

The total revenue from operations increased 8% year-on-year to Rs.12,958.8 crore in the fourth quarter ended March, according to its exchange filing on Thursday. That was below Rs.13,254 crore average revenue estimated by analysts surveyed by Bloomberg.

The ...